Evidence map›Paper›PMID 23263004›Full record

ArticleAntimicrobial agents and chemotherapy2013

Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa.

Ousman Secka, Douglas E Berg, Martin Antonio, Tumani Corrah, Mary Tapgun, Robert Walton, Vivat Thomas, Juan J Galano, Javier Sancho, Richard A Adegbola and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Flavodoxins as Novel Therapeutic Targets againstInternational journal of molecular sciences · 2020
    Review
  7. High Prevalence of Antibiotic Resistance in IranianJournal of clinical medicine · 2019
    Article
  8. Infections withWorld journal of gastroenterology · 2019
    Review
  9. Article
  10. Canadian journal of gastroenterology & hepatology · 2019
    Article
  11. Saudi journal of biological sciences · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Ousman SeckaMedical Research Council Unit, Fajara, The Gambia. osecka@mrc.gm
Douglas E Berg
Martin Antonio
Tumani Corrah
Mary Tapgun
Robert Walton
Vivat Thomas
Juan J Galano
Javier Sancho
Richard A Adegbola
Julian E Thomas
MRC Unit the Gambia · GMMedical Research Council · GBUniversidad de Zaragoza · ESNewcastle University · GBWashington University in St. Louis · US

Funding

NOVEL TRANSPOSONS AND PLASTICITY ZONES OF HELICOBACTER PYLORIR21AI088337 · NIAID · WASHINGTON UNIVERSITY · PI BERG, DOUGLAS EUGENE · 2010 to 2011
$416k
HELICOBACTER PYLORI GENOME SEQUENCE EVOLUTIONR21AI078237 · NIAID · WASHINGTON UNIVERSITY · PI BERG, DOUGLAS EUGENE · 2009 to 2010
$266k
Genotypes of Helicobacter Pylori in West AfricaR03AI061308 · NIAID · MEDICAL RESEARCH LABS-GAMBIA · PI ADEGBOLA, RICHARD A · 2004 to 2005
$108k
NIAID NIH HHS R03 AI061308NIAID NIH HHS R03-AI061308NIAID NIH HHS R21 AI078237NIAID NIH HHS R21-AI078237NIAID NIH HHS R21 AI088337NIAID NIH HHS R21-AI088337
6 · The paper itself

Abstract

Helicobacter pylori is a globally important and genetically diverse gastric pathogen that infects most people in developing countries. Eradication efforts are complicated by antibiotic resistance, which varies in frequency geographically. There are very few data on resistance in African strains. Sixty-four Gambian H. pylori strains were tested for antibiotic susceptibility. The role of rdxA in metronidazole (Mtz) susceptibility was tested by DNA transformation and sequencing; RdxA protein variants were interpreted in terms of RdxA structure. Forty-four strains (69%) were resistant to at least 8 μg of Mtz/ml. All six strains from infants, but only 24% of strains from adults, were sensitive (P = 0.0031). Representative Mtz-resistant (Mtz(r)) strains were rendered Mtz susceptible (Mtz(s)) by transformation with a functional rdxA gene; conversely, Mtz(s) strains were rendered Mtz(r) by rdxA inactivation. Many mutations were found by Gambian H. pylori rdxA sequencing; mutations that probably inactivated rdxA in Mtz(r) strains were identified and explained using RdxA protein's structure. All of the strains were sensitive to clarithromycin and erythromycin. Amoxicillin and tetracycline resistance was rare. Sequence analysis indicated that most tetracycline resistance, when found, was not due to 16S rRNA gene mutations. These data suggest caution in the use of Mtz-based therapies in The Gambia. The increasing use of macrolides against respiratory infections in The Gambia calls for continued antibiotic susceptibility monitoring. The rich variety of rdxA mutations that we found will be useful in further structure-function studies of RdxA, the enzyme responsible for Mtz susceptibility in this important pathogen.

Indexed as

MutationAdolescentAdultAgedAmoxicillinAnti-Bacterial AgentsBacterial ProteinsChildChild, PreschoolClarithromycinDNA Mutational AnalysisDrug Resistance, BacterialErythromycinFemaleGambiaHelicobacter InfectionsAmoxicillinAnti-Bacterial AgentsBacterial ProteinsClarithromycinErythromycinMetronidazoleNitroreductasesRdxA protein, Helicobacter pyloriRNA, Ribosomal, 16STetracycline

Identifiers

PMID23263004
PMCPMC3591906
OpenAlexW2112215083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.